Discontinued — last reported Q4 '25
Stryker Interest Paid remained flat by 0.0% to $145.50M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 47.0%, from $99.00M to $145.50M. Over 4 years (FY 2021 to FY 2025), Interest Paid shows an upward trend with a 15.7% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase in interest paid relative to debt levels may signal rising borrowing costs or higher leverage, while a decrease may indicate debt reduction or refinancing at lower rates.
The total cash outflow for interest payments on debt obligations, typically disclosed as a supplemental item in the cash...
Essential for comparing the cost of capital and debt burden across peers in the pharmaceutical industry.
interest_paid| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | $325.00M | $324.00M | $356.00M | $396.00M | $582.00M |
| YoY Change | — | -0.3% | +9.9% | +11.2% | +47.0% |